Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respiratory Safety of Lemborexant in OSA and COPD
NCT04647383Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lemborexant in Insomnia (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Apnea-Hypopnea Index at Day 8 and Peripheral Oxygen Saturation During TST at Day 8. Started Jan 2021; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04647383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647383.